CBD epilepsy treatment wins unanimous approval from FDA
CBD epilepsy treatment wins unanimous approval from FDA advisers
A CBD treatment for epilepsy is closer to becoming the first cannabis medicine approved for the U.S. market.
A panel of government health advisers gave a unanimous recommendation Thursday to the U.S. Food and Drug Administration to approve Epidiolex, a CBD medicine for rare epilepsy conditions that don’t respond to other drugs.
British drugmaker GW Pharmaceuticals is seeking FDA approval to sell the drug in the United States.
“We owe it to these patients and families to identify new treatments,” said Dr. Orrin Devinsky, a neurologist who specializes in epilepsy at New York University.
The panel voted 13-0 to suggest FDA approval after hearing presentations on the drug’s effectiveness and safety.
On Tuesday, the FDA had posted its own review of Epidolex, saying that “data in the application appears to support approval” for the new drug.
The FDA’s physicians said the drug has a low potential for abuse, and that it doesn’t produce euphoric effects seen from THC.
The advisory panel’s recommendation doesn’t bind the agency to approving Epidiolex, but its recommendations carry serious weight.
The FDA has said it will issue a decision by late June.
A representative from GW Pharmaceuticals declined to say whether the CBD in Epidiolex comes from hemp or marijuana, simply describing the source as a “proprietary strain of the cannabis plant.”
He also declined to say where the plants are being grown.
When asked, the FDA said cannabis likely would be rescheduled in the Controlled Substances Act if Epidiolex is approved, though the final decision would be made by the U.S. Drug Enforcement Administration and the FDA’s parent agency, the U.S. Department of Health and Human Services.
7
Rocky Mountain High Brands, Inc. (RMHB) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Top 5 Most Recently Viewed Articles
Important Milestones for AB Akola Group Investors in 2025 Understanding the critical dates for investors is essential in navigating the financial landscape. AB Akola Group has outlined key disclosure dates for the year 2025, which will serve as pivotal moments for shareholders and potential investors alike. February Releases: Unaudited Financial Reports In February, the...
Continue Reading
ValOre’s Latest Exploration Progress at Salvador ValOre Metals Corp. has shared new results from the Salvador target within the Pedra Branca Platinum Group Elements (PGE) Project. Early work—Trado® auger drilling paired with rock sampling—has confirmed in-situ PGE mineralization. It’s a clear step forward in understanding what’s driving the system at Salvador...
Continue Reading
Aerospacelab Expands Operations in the U.S. Aerospacelab, Inc. has proudly opened its new satellite manufacturing facility, a strategic move that places the company in the heart of the booming aerospace industry and responds to the growing demand for satellite technology. Overview of the New Manufacturing Facility This state-of-the-art facility spans 35,000 square feet,...
Continue Reading
Introduction to Lighthouse Villa Canada faces a significant challenge in providing affordable housing, particularly for its senior citizens. In a move to address these urgent needs, funding has been announced for Lighthouse Villa, an innovative housing project that aims to enhance the living conditions of independent seniors. Project Overview Lighthouse Villa, located at...
Continue Reading
Investors Rally for Justice in Aehr Test Systems Case Aehr Test Systems (NASDAQ: AEHR) is currently facing a significant securities fraud lawsuit that has captured the attention of investors and legal experts alike. The law firm of Rosen is spearheading this movement and reminding all purchasers of Aehr securities that they may have an opportunity to take action....
Continue Reading
